Replimune (REPL) began trading on the Nasdaq on 20 July 2018

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 52
• Founded in 2015 
• Headquartered in Woburn, Massachusetts
• http://www.replimune.com

Replimune priced 6.7 mln share IPO at $15.00, the midpoint of the expected $14.00-16.00 range.
Ppened for trading at $16